Skip to main content
. 2024 Sep 4;16(17):3071. doi: 10.3390/cancers16173071

Figure 1.

Figure 1

Potential mechanisms of enhanced anticancer T immune responses with the combination of pembrolizumab and enfortumab vedotin.